Breaking Hematology Research Updates: New Trials, Gene Therapies & Global Hematology Breakthroughs 💉🌍
This week’s roundup brings major advances in hematology, oncology, and immunotherapy research—from first-line lymphoma treatments to next-generation CAR-T therapies and CRISPR diagnostics. Here’s what’s making headlines:
🔬 Calquence earns EU recommendation for first-line treatment of mantle cell lymphoma, showing a 27 percent reduction in disease progression and extending median PFS to 66.4 months.
🌍 Yingli Pharma’s linperlisib cleared for a global Phase 3 trial in relapsed/refractory peripheral T-cell lymphoma.
🇬🇧 NICE approves brentuximab vedotin (Adcetris) for stage 3/4 CD30-positive Hodgkin lymphoma, now accessible through the NHS Cancer Drugs Fund.
🧪 Xcellbio’s AVATAR™ tech powers potency testing for bluebird bio’s LYFGENIA gene therapy in sickle cell disease patients aged 12 and above.
🧬 Sanofi’s rilzabrutinib receives orphan drug designation for warm autoimmune hemolytic anemia and IgG4-related disease, with promising steroid-sparing results.
💡 MDC-CAR-BCMA001 CAR-T therapy shows complete responses and eighty-three percent overall survival at 12 months in myeloma and AL amyloidosis patients.
📈 FLU/BU4 conditioning regimen demonstrates improved three-year survival in older AML patients versus conventional approaches.
🧠 CRISPR-based test detects acute promyelocytic leukemia early, enabling life-saving intervention in a highly curable cancer.
🧬 LILRB1 identified as a new CAR-T target in CD19-resistant blood cancers, including monocytic AML and B-cell malignancies.
💉 Amneal and Shilpa launch BORUZU™, a ready-to-use bortezomib injection for myeloma and MCL, now available in the U.S. with a unique J-code.
📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on hematology research
#HematologyResearch #OncologyNews #CARTTherapy #CRISPRDiagnostics #GeneTherapy #MantleCellLymphoma #HodgkinLymphoma #Sanofi #BluebirdBio #Calquence #Rilzabrutinib #LucidQuest